AbbVie (NYSE:ABBV) Upgraded at Hsbc Global Res

Hsbc Global Res upgraded shares of AbbVie (NYSE:ABBV) from a hold rating to a strong-buy rating in a research report sent to investors on Wednesday,Zacks.com reports.

ABBV has been the topic of a number of other reports. Wells Fargo & Company lifted their price objective on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Evercore ISI boosted their target price on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research note on Monday, September 22nd. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 30th. Guggenheim lifted their price target on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Finally, Citigroup reduced their price target on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $244.55.

AbbVie Stock Down 0.2%

ABBV opened at $223.45 on Wednesday. The company has a market capitalization of $394.92 billion, a P/E ratio of 169.28, a P/E/G ratio of 1.21 and a beta of 0.36. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. The firm’s fifty day moving average price is $227.25 and its two-hundred day moving average price is $209.59. AbbVie has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period last year, the firm earned $3.00 EPS. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts anticipate that AbbVie will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is 496.97%.

Institutional Trading of AbbVie

A number of hedge funds and other institutional investors have recently modified their holdings of ABBV. Brighton Jones LLC raised its holdings in AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the period. Vestmark Advisory Solutions Inc. boosted its position in shares of AbbVie by 84.3% in the 1st quarter. Vestmark Advisory Solutions Inc. now owns 38,888 shares of the company’s stock worth $8,148,000 after purchasing an additional 17,788 shares during the last quarter. OneAscent Investment Solutions LLC acquired a new stake in shares of AbbVie during the first quarter worth $330,000. Finally, Kovitz Investment Group Partners LLC increased its holdings in AbbVie by 42.7% in the first quarter. Kovitz Investment Group Partners LLC now owns 93,218 shares of the company’s stock valued at $19,531,000 after purchasing an additional 27,890 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.